---
title: "IceCure Medical publishes investor presentation on ProSense FDA-cleared cryoablation treatment for low-risk breast cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292404676.md"
description: "IceCure Medical released an investor presentation detailing commercialization plans for its FDA-cleared ProSense cryoablation system, the only on-label minimally invasive treatment for low-risk breast cancer. The company highlights a $1.2 billion U.S. market opportunity and strong clinical data from the ICE3 study. Additionally, IceCure announced plans for the ChoICE post-marketing study involving approximately 400 patients, targeting initiation in H2 2026."
datetime: "2026-07-12T14:08:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292404676.md)
  - [en](https://longbridge.com/en/news/292404676.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292404676.md)
generator: "portal-rs"
---

# IceCure Medical publishes investor presentation on ProSense FDA-cleared cryoablation treatment for low-risk breast cancer

-   IceCure outlined U.S. commercialization plans for its ProSense cryoablation system, positioned as the only on-label minimally invasive local treatment for low-risk breast cancer. \* Management pegged the U.S. breast cancer opportunity at more than $1.2 billion in total addressable market, citing an 8+ year competitive head start. \* ICE3 breast cancer study data cited 4.3% ipsilateral recurrence at 5 years, 96.7% survival, 24-hour recovery, no re-excision. \* FDA-cleared post-marketing ChoICE study planned for about 400 patients at at least 30 U.S. sites, with initiation targeted for H2 2026. \* Company cited regulatory approvals in 27 countries, 47 granted patents, 64 employees, manufacturing capacity positioned to scale. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on July 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ICCM.US](https://longbridge.com/en/quote/ICCM.US.md)

## Related News & Research

- [IceCure says West Cancer Center begins enrollment for ChoICE breast cancer cryoablation study](https://longbridge.com/en/news/296489702.md)
- [08:10 ETWest Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation](https://longbridge.com/en/news/296488705.md)
- [IceCure highlights 5-year ICE3 breast cancer trial showing 3.1% recurrence rate after cryoablation](https://longbridge.com/en/news/295804964.md)
- [09:10 ETIceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation](https://longbridge.com/en/news/295805121.md)
- [IceCure Medical director David Salton files initial beneficial ownership statement](https://longbridge.com/en/news/296104736.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**